Axsome TherapeuticsAXSM
AXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 589
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
210% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 29
37% more capital invested
Capital invested by funds: $3.15B [Q4 2024] → $4.32B (+$1.17B) [Q1 2025]
28% more call options, than puts
Call options by funds: $111M | Put options by funds: $86.5M
20% more funds holding
Funds holding: 290 [Q4 2024] → 348 (+58) [Q1 2025]
9% more funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 12 (+1) [Q1 2025]
0.85% less ownership
Funds ownership: 76.71% [Q4 2024] → 75.86% (-0.85%) [Q1 2025]
11% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 114
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$150
44%
upside
Avg. target
$181
73%
upside
High target
$216
107%
upside
8 analyst ratings
8 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Leonid Timashev | 79%upside $186 | Outperform Maintained | 12 Jun 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 73%upside $180 | Buy Reiterated | 10 Jun 2025 |
Needham Ami Fadia | 44%upside $150 | Buy Maintained | 9 Jun 2025 |
Oppenheimer Matthew Hershenhorn | 78%upside $185 | Outperform Initiated | 3 Jun 2025 |
Wells Fargo Cerena Chen | 59%upside $165 | Overweight Maintained | 6 May 2025 |
Financial journalist opinion
Based on 6 articles about AXSM published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington.
Positive
The Motley Fool
1 week ago
2 Soaring Stocks Wth More Upside Potential
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left.
Negative
Zacks Investment Research
1 week ago
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
2 weeks ago
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming investor conferences in June:
Neutral
GlobeNewsWire
2 weeks ago
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome's product SUNOSI® (solriamfetol). The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hetero of an Abbreviated New Drug Application to the U.S. Food and Drug Administration seeking approval to market a generic version of SUNOSI in the United States. Under the terms of the settlement agreement, Axsome will grant Hetero a license to sell its generic version of SUNOSI beginning on or after September 1, 2040, if pediatric exclusivity is granted for SUNOSI, or on or after March 1, 2040, if no pediatric exclusivity is granted, subject to FDA approval and conditions and exceptions customary for agreements of this type.
Positive
The Motley Fool
3 weeks ago
3 High-Flying Stocks That Could Soar Even More
Many investors love the "big mo." That's short for "big momentum.
Positive
The Motley Fool
1 month ago
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Explore the exciting world of Axsome Therapeutics (AXSM -1.70%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Neutral
GlobeNewsWire
1 month ago
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a $570 million term loan and revolving credit facility with funds managed by Blackstone Life Sciences and Blackstone Credit & Insurance (“Blackstone”). Concurrent with this new facility, Axsome has retired its previous term loan with Hercules Capital.
Positive
The Motley Fool
1 month ago
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
Regardless of how stocks are performing right now, history tells us that the market tends to generate solid returns over long periods. Investors can do even better than the average market performance by buying shares of companies likely to beat broader equities.
Positive
The Motley Fool
1 month ago
3 Monster Stocks in the Making
Think of some of the biggest and most successful stocks on the market. Now, go back 20 or 30 years.
Charts implemented using Lightweight Charts™